INVESTOR ALERT: Class Action Lawsuit Filed Against uniQURE N.V.

Kirby McInerney LLP, a law firm, has announced the filing of a class-action lawsuit on behalf of investors who bought securities from uniQURE N.V. (referred to as “uniQURE” or the “Company”) (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, which is known as the Class Period.

Investors who have suffered losses on their investments in uniQURE have until April 13, 2026, to request to be appointed as the lead plaintiff. It is crucial to note that after this date, lead plaintiff applications will not be considered by the courts. If investors choose not to take action, they may still be involved in the lawsuit as absent class members. More details regarding the lawsuit can be obtained by contacting the firm directly.

The lawsuit centers around uniQURE’s Pivotal Study design, where the comparison of its results was allegedly not fully authorized by the FDA. Additionally, the Company is accused of downplaying the probability of needing to extend its BLA timeline to conduct further studies despite the seemingly positive results from the Pivotal Study.

On November 3, 2025, uniQURE revealed that the FDA no longer concurred that data from the Phase I/II studies of AMT-130 compared to an external control were sufficient to support a BLA submission. The uncertainty surrounding the timing of the AMT-130 BLA submission led to a significant decrease in uniQURE’s share price, dropping by $33.40 per share, or around 49.33%, from $67.69 per share on October 31, 2025, to $34.29 on November 3, 2025.

In relation to the lead plaintiff appointment process, the federal securities laws enable any investor who purchased eligible securities during the Class Period to seek appointment as the lead plaintiff in the class-action lawsuit. Typically, the court appoints the investor or investors with the most substantial financial losses, considering their ability to represent the entire class, rather than solely focusing on those with the largest investment portfolios. Lead plaintiffs wield influence over case strategy, participate in settlement decisions, and play a role in distributing settlement funds among class members.

Investors who bought uniQURE securities, possess relevant information, or wish to understand more about the investigation are encouraged to reach out to Lauren Molinaro of Kirby McInerney LLP via email or by completing the provided contact form. Kirby McInerney LLP, a New York-based law firm, specializes in securities, antitrust, whistleblower, and consumer litigation and has successfully recovered billions of dollars on behalf of shareholders in securities litigation cases. More information about the law firm can be accessed on their website.